{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:30:33Z","timestamp":1785148233656,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acute graft-versus-host disease (aGVHD), particularly with gastrointestinal (GI) involvement, remains a life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). Despite corticosteroids and ruxolitinib as first- and second-line therapies, up to 50% of patients develop refractory disease, with limited evidence guiding third-line interventions. Anti-thymocyte globulin (ATG), historically used in conditioning regimens, has shown variable efficacy in steroid-refractory aGVHD, but its role in patients previously exposed to ATG prophylaxis remains underexplored. Here, we report the case of a 19-year-old male with severe steroid- and ruxolitinib-refractory GI aGVHD, successfully treated with low-dose antithymocyte globulin (ATG) after failing multiple therapies (mycophenolate mofetil, anti-CD25 monoclonal antibody, mesenchymal stem cells, and methotrexate). This case underscores that, despite the prior use of ATG in the conditioning regimen and the multitude of available treatment options for refractory aGVHD, ATG can still be considered as a viable salvage therapy in situations where certain newer agents are not accessible.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1610071","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:10:34Z","timestamp":1753416634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Successful treatment of steroid- and ruxolitinib-refractory gastrointestinal acute graft-versus-Host disease with anti-thymocyte globulin"],"prefix":"10.3389","volume":"16","author":[{"given":"Lulu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0544-y","article-title":"Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"54","author":"Axt","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0804-2","article-title":"Treatment and unmet needs in steroid-refractory acute graft-versus-host disease","volume":"34","author":"Malard","year":"2020","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease","volume":"52","author":"Garcia-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1992383","article-title":"New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD)","volume":"25","author":"Choe","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","article-title":"The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation","volume":"95","author":"Hill","year":"2000","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000960","article-title":"How I treat steroid-refractory acute graft-versus-host disease","volume":"135","author":"Martin","year":"2020","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.128","article-title":"Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations","volume":"8","author":"Nishihori","year":"2016","journal-title":"Immunotherapy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2014.11.008","article-title":"Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin","volume":"43","author":"Nishimoto","year":"2015","journal-title":"Exp Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050310","article-title":"ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival","volume":"75","author":"Dugan","year":"1997","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1083-8791(00)70036-x","article-title":"A randomized trial comparing prednisone with antithymocyte globulin\/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease","volume":"6","author":"Cragg","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.59","article-title":"Prognosis of grade 3\u20134 acute GVHD continues to be dismal","volume":"48","author":"Jamani","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738625","article-title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","volume":"129","author":"Socie","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.03.007","article-title":"Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells","volume":"54","author":"Delacher","year":"2021","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122014","article-title":"Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease","volume":"4","author":"Yang","year":"2019","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/s41467-024-48574-w","article-title":"IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice","volume":"15","author":"Muckenhuber","year":"2024","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:10:36Z","timestamp":1753416636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1610071"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1610071","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1610071"}}